COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA

COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA

PURPOSE:To provide a stabilized composition preventing the adsorption of IL-1beta activated substance to the wall of a container and having the improved maintenance of the activity thereof by containing the IL-1beta activated substance and human serum albumin and/or a saccharide and a surfactant. CO...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SUGAWARA YUJI, KAISE HIROTSUGU
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SUGAWARA YUJI
KAISE HIROTSUGU
description PURPOSE:To provide a stabilized composition preventing the adsorption of IL-1beta activated substance to the wall of a container and having the improved maintenance of the activity thereof by containing the IL-1beta activated substance and human serum albumin and/or a saccharide and a surfactant. CONSTITUTION:The stabilized composition contains interleukin-1beta (IL-1beta) or a derivative thereof and (A) A1: human serum albumin and/or A2: a saccharide, preferably mannitol, inositol, sucrose, maltose or dextran and (B) a surfactant, preferably a polyoxyethylene glycol sorbitan alkyl ester surfactant, sorbitan monoacyl ester surfactant or fatty acid glyceride surfactant preferably in an A1: A2: B ratio of 0.01-10mg: 1-100mg: 0.001-0.1mg per mug of the IL-1beta activated substance. The further addition of a sulfur-containing reducing agent, e.g., cysteine or thioglycolic acid) to the composition achieves the further improvement of the stabilization effect.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPH02138222A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPH02138222A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPH02138222A3</originalsourceid><addsrcrecordid>eNrjZNB19vcN8A_2DPH091Nw8w9SCA5xdPL08Yzy9HNX8PQLcQ3ycQ319vTTNXRyDXHkYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxXgEeBkaGxhZGRkaOxsSoAQDibCXd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA</title><source>esp@cenet</source><creator>SUGAWARA YUJI ; KAISE HIROTSUGU</creator><creatorcontrib>SUGAWARA YUJI ; KAISE HIROTSUGU</creatorcontrib><description>PURPOSE:To provide a stabilized composition preventing the adsorption of IL-1beta activated substance to the wall of a container and having the improved maintenance of the activity thereof by containing the IL-1beta activated substance and human serum albumin and/or a saccharide and a surfactant. CONSTITUTION:The stabilized composition contains interleukin-1beta (IL-1beta) or a derivative thereof and (A) A1: human serum albumin and/or A2: a saccharide, preferably mannitol, inositol, sucrose, maltose or dextran and (B) a surfactant, preferably a polyoxyethylene glycol sorbitan alkyl ester surfactant, sorbitan monoacyl ester surfactant or fatty acid glyceride surfactant preferably in an A1: A2: B ratio of 0.01-10mg: 1-100mg: 0.001-0.1mg per mug of the IL-1beta activated substance. The further addition of a sulfur-containing reducing agent, e.g., cysteine or thioglycolic acid) to the composition achieves the further improvement of the stabilization effect.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>1990</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19900528&amp;DB=EPODOC&amp;CC=JP&amp;NR=H02138222A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19900528&amp;DB=EPODOC&amp;CC=JP&amp;NR=H02138222A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SUGAWARA YUJI</creatorcontrib><creatorcontrib>KAISE HIROTSUGU</creatorcontrib><title>COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA</title><description>PURPOSE:To provide a stabilized composition preventing the adsorption of IL-1beta activated substance to the wall of a container and having the improved maintenance of the activity thereof by containing the IL-1beta activated substance and human serum albumin and/or a saccharide and a surfactant. CONSTITUTION:The stabilized composition contains interleukin-1beta (IL-1beta) or a derivative thereof and (A) A1: human serum albumin and/or A2: a saccharide, preferably mannitol, inositol, sucrose, maltose or dextran and (B) a surfactant, preferably a polyoxyethylene glycol sorbitan alkyl ester surfactant, sorbitan monoacyl ester surfactant or fatty acid glyceride surfactant preferably in an A1: A2: B ratio of 0.01-10mg: 1-100mg: 0.001-0.1mg per mug of the IL-1beta activated substance. The further addition of a sulfur-containing reducing agent, e.g., cysteine or thioglycolic acid) to the composition achieves the further improvement of the stabilization effect.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1990</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB19vcN8A_2DPH091Nw8w9SCA5xdPL08Yzy9HNX8PQLcQ3ycQ319vTTNXRyDXHkYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxXgEeBkaGxhZGRkaOxsSoAQDibCXd</recordid><startdate>19900528</startdate><enddate>19900528</enddate><creator>SUGAWARA YUJI</creator><creator>KAISE HIROTSUGU</creator><scope>EVB</scope></search><sort><creationdate>19900528</creationdate><title>COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA</title><author>SUGAWARA YUJI ; KAISE HIROTSUGU</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPH02138222A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1990</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>SUGAWARA YUJI</creatorcontrib><creatorcontrib>KAISE HIROTSUGU</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SUGAWARA YUJI</au><au>KAISE HIROTSUGU</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA</title><date>1990-05-28</date><risdate>1990</risdate><abstract>PURPOSE:To provide a stabilized composition preventing the adsorption of IL-1beta activated substance to the wall of a container and having the improved maintenance of the activity thereof by containing the IL-1beta activated substance and human serum albumin and/or a saccharide and a surfactant. CONSTITUTION:The stabilized composition contains interleukin-1beta (IL-1beta) or a derivative thereof and (A) A1: human serum albumin and/or A2: a saccharide, preferably mannitol, inositol, sucrose, maltose or dextran and (B) a surfactant, preferably a polyoxyethylene glycol sorbitan alkyl ester surfactant, sorbitan monoacyl ester surfactant or fatty acid glyceride surfactant preferably in an A1: A2: B ratio of 0.01-10mg: 1-100mg: 0.001-0.1mg per mug of the IL-1beta activated substance. The further addition of a sulfur-containing reducing agent, e.g., cysteine or thioglycolic acid) to the composition achieves the further improvement of the stabilization effect.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_JPH02138222A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title COMPOSITION FOR STABILIZING INTERLEUKIN-1BETA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T10%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SUGAWARA%20YUJI&rft.date=1990-05-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPH02138222A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true